Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study by Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, Olivier Tournilhac, Luc-Matthieu Fornecker, Frédéric Maloisel, Lauris Gastaud, Eric Durot, Adrian Tempescul, Thorsten Braun, Vadim Ivanov, Brieuc Cherel, Caroline Serrier, Jeremy Delage, Abderrazak El Yamani, Baptiste Delapierre, Laure Lebras, Elsa Lestang, Camille Villesuzanne, Philippe Agape, Guillaume Escure, Ludovic Fouillet, Christophe Nicol, Gaëlle Olivier, Anthony Levy, Anne-Sophie Le Bris, Ophélie Cassuto, Laura Jacquemelle, Corinne Haioun, Charles Herbaux

Get full text